N-((S)-4-(Benzylamino)-3-((S)-2-(3-(1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazol-6-yl)ureido)-3-(3,4-difluorophenyl)propanamido)-4-oxobutyl)pent-4-ynamide (12, DG-207) Notice If using 11b, it is necessary to convert this compound to the bis HCl salt (11a) prior to performing this EDC coupling reaction as it has been seen the formate salt will give a mixture of products

N-((S)-4-(Benzylamino)-3-((S)-2-(3-(1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazol-6-yl)ureido)-3-(3,4-difluorophenyl)propanamido)-4-oxobutyl)pent-4-ynamide (12, DG-207) Notice If using 11b, it is necessary to convert this compound to the bis HCl salt (11a) prior to performing this EDC…

CTLA\4, cytotoxic T\lymphocyteCassociated protein 4; Foxp3, forkhead protein 3; GARP, glycoprotein A repetitions predominant; HLA\DR, human leukocyte antigen\DR isotype; nR, non\responder; PD\1, programmed cell death protein 1; R, responder; Treg, regulatory T cells To quantify the T cell\to\Treg composition in the peripheral blood, we calculated the corresponding T cell\to\Treg ratios

CTLA\4, cytotoxic T\lymphocyteCassociated protein 4; Foxp3, forkhead protein 3; GARP, glycoprotein A repetitions predominant; HLA\DR, human leukocyte antigen\DR isotype; nR, non\responder; PD\1, programmed cell death…